As part of our series focussing on medicines in Australia, we have added a product review of the use of ibrutinib with venetoclax for chronic lymphocytic leukaemia, now a funded first-line option.
This review discusses the evidence supporting the use of ibrutinib in combination with venetoclax for previously untreated chronic lymphocytic leukaemia in adults. It provides commentary from Professor Con Tam, Head of the Lymphoma Service at Alfred Health, and Professor of Haematology at Monash University.
Please login below to download this issue (PDF)